Administrative Core

行政核心

• 批准号: 7671867
• 负责人: PHILIP Frederick SPARLING
• 金额: $ 28.45万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-15 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7671867
• 关键词: Academia; Alabama; Alphavirus; Animal Model; Antibodies; Antiviral Agents; Area; Bacillus anthracis spore; Bacteriology; Binding; Biology; Breathing; Categories; Chikungunya virus; Clinical; Clostridium; Collaborations; Commit; Communicable Diseases; Complement; Coronavirus; Dengue; Dengue Virus; Development; Disease; Drops; Emergency Situation; Emerging Communicable Diseases; Encephalitis Viruses; Environment; Epitopes; Extreme drug resistant tuberculosis; Flavivirus; Florida; Foundations; Francisella tularensis; Funding; Germination; Goals; Gram-Positive Bacteria; Health; Immune; Immune response; Immune system; Immunology; Individual; Infection; Infectious Agent; Institution; Intervention; Lead; Ligands; Lung; Mission; Modeling; Mutation; Natural Immunity; Nature; North Carolina; Pathogenesis; Pathway interactions; Pharmaceutical Preparations; Plague; Poxviridae; Prevention; Private Enterprises; Proteins; Public Health; Reagent; Reproduction spores; Research; Research Personnel; Research Training; Risk; Role; Route; Science; Scientist; Screening procedure; Structure; Sum; Testing; Translating; Tropism; Tularemia; Universities; Vaccines; Viral; Virulence; Virus; West Nile virus; Work; Zoonoses; base; biodefense; disorder risk; drug development; drug discovery; effective therapy; experience; human disease; influenzavirus; interest; member; mouse model; multidisciplinary; novel; novel vaccines; pathogen; pathogenic bacteria; programs; public-private partnership; receptor; response; structural biology; vaccine development; virology; virus pathogenesis

We are proud to present the SERCEB (Southeast Regional Center of Excellence for Emerging Infections and Biodefense) plan for the next five years of research, training and emergency response. Our organizing theme is "host-pathogen interactions: opportunities for intervention." We bring together an integrated and experienced team of superb investigators in virology, bacteriology, immunology, drug discovery and vaccine development whose ability to work together has been clearly demonstrated in the past five years. We believe our group is second to none, and look forward to the challenges and opportunities ahead with great confidence in our ability to deliver the highest quality discovery science, and in our ability to deliver clinically useful products. We work together in synergistic teams that span boundaries between universities, between basic scientists and public health workers,.and between academia and private enterprise. We are stronger by far than the sum of our individual parts. Our focus is in areas where our particular strengths add to or complement those of our partners throughout the national Regional Centers of Excellence (RCE) program. SERCEB is multidisciplinary team based in Region IV. The Prime Institution is the University of North Carolina Chapel Hill (UNC), and the other principal consortium members include Duke University, Emory University, Vanderbilt University, the University of Florida (Gainesville), and the University of Alabama at Birmingham. Our primary goal is to assist the nation in developing and deploying effective and rapid responses to biodefense and emerging infectious diseases threats. To this end, we will discover new therapies and principles by which effective new vaccines can be developed. Our pathways to discovery include better understanding of the pathogenic mechanisms by which pathogens cause disease and the nature of the immune responses against them. Hence, mechanistic studies on pathogenesis and animal models will also be a focus of study. We will concentrate on areas that offer promise for discovery of broad targets for therapy or prevention. We emphasize pathogen interactions with the innate immune system, an area of great SERCEB strength that offers excellent opportunities for discovery of broadly effective therapies. Discovery of new therapies also includes a focused screening and drug development team effort, which although not directly derived from studies of basic pathogenesis, depends in part on studies of pathogenesis to validate targets. Vaccine discovery is based on identification of crucial shared protective epitopes and protective, as opposed to deleterious, immune responses.

我们很自豪地介绍SERCEB（东南地区新兴感染卓越中心）， 生物防御）计划，为未来五年的研究，培训和应急反应。我们的组织主题 是“宿主-病原体相互作用：干预的机会。“我们汇集了一个综合的， 在病毒学、细菌学、免疫学、药物发现和疫苗方面经验丰富的优秀研究人员团队 在过去五年中，这些国家共同努力的能力得到了清楚的证明。我们认为 我们的集团是首屈一指的，并期待着未来的挑战和机遇充满信心 我们有能力提供最高质量的发现科学，我们有能力提供临床有用的 产品.我们在跨越大学之间、基础教育之间、 科学家和公共卫生工作者之间，以及学术界和私营企业之间。我们比以前更强大 比我们每个人的总和还要大我们的重点是在我们的特殊优势增加或补充的领域 我们的合作伙伴在整个国家区域卓越中心（RCE）计划。 SERCEB是位于第四区的多学科团队。主要机构是北卡罗来纳州大学 查佩尔山（查珀尔山），其他主要财团成员包括杜克大学，埃默里大学， 范德比尔特大学、佛罗里达大学（盖恩斯维尔）和位于伯明翰的亚拉巴马大学。我们 主要目标是协助国家制定和部署有效和快速的应对措施， 生物防御和新出现的传染病威胁。为此，我们将发现新的疗法， 这些原则可以开发有效的新疫苗。我们的发现之路包括更好的 了解病原体引起疾病的致病机制和病原体的性质， 免疫系统对它们的反应。因此，对发病机制和动物模型的机制研究将 也是研究的重点。我们将把重点放在有希望发现广泛目标的领域 用于治疗或预防。我们强调病原体与先天免疫系统的相互作用， 强大的SERCEB优势，为发现广泛有效的疗法提供了绝佳的机会。 新疗法的发现还包括集中筛选和药物开发团队的努力， 虽然不是直接从基本发病机制的研究中得出的，但部分取决于发病机制的研究， 确认目标疫苗的发现是基于关键的共享保护性表位的鉴定， 保护性的，而不是有害的，免疫反应。